RT Journal Article
SR Electronic
T1 The impact and progression of the COVID-19 pandemic in Bulgaria in its first two years
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.09.01.22279496
DO 10.1101/2022.09.01.22279496
A1 Rangachev, Antoni
A1 Marinov, Georgi K.
A1 Mladenov, Mladen
YR 2022
UL http://medrxiv.org/content/early/2022/09/02/2022.09.01.22279496.abstract
AB After initially having low levels of SARS-CoV-2 infections for much of the year, at the end of 2020 Bulgaria experienced a major epidemic surge, which caused the highest recorded excess mortality in Europe and among the highest in the word (Excess Mortality Rate, or EMR ∼ 0.25%). Two more major waves followed in 2021, followed by another one in early 2022. In this study we analyze the temporal and spatial patterns of excess mortality at the national and local levels and across different demographic groups in Bulgaria, and compare those at the European level. The country has continued to exhibit the previous pattern of extremely high excess mortality as measured both by crude mortality metrics (EMR ∼ 1.05% up to the end of March 2022) and by standardized ones – Potential Years of Life Lost (PYLL) and Aged-Standardized Years of life lost Rate (ASYR). Unlike Western Europe, the bulk of excess mortality in Bulgaria, as well as in several other countries in Eastern Europe, occurred in the second year of the pandemic, likely related to the differences in the levels of vaccination coverage between these regions. We also observe even more extreme levels of excess mortality at the regional level and in some subpopulations (e.g. total EMR values for males ≥ 2% and EMR values for males aged 40-64 ≥ 1% in certain areas). We discuss these observations in light of the estimates of infection fatality rate (IFR) and eventual population fatality rate (PFR) made early in the course of the pandemic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementA.R. would like to acknowledge the financial support of a "Petar Beron i NIE" fellowship [KP-06-D15-1] from the Bulgarian Science Fund.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethics Committee of IMI-BAS (Institute of Mathematics and Informatics, Bulgarian Academy of Sciences) gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll datasets and associated code can be found at https://github.com/Mlad-en/Bulgaria_Regional_Mortality and https://github.com/Mlad-en/COV-BG.